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Maize DAS-40278-9 was developed by direct Whiskers-mediated transformation to express the
aryloxyalkanoate dioxygenase-1 (AAD-1) protein, conferring tolerance to 2,4-dichlorophenoxyacetic acid
(2,4-D) and aryloxyphenoxypropionate (AOPP) herbicides. The molecular characterisation of maize
DAS-40278-9 did not raise safety issues. The agronomic, phenotypic and compositional characteristics of
maize DAS-40278-9 tested under ﬁeld conditions revealed no differences between maize DAS-40278-9
and its non-genetically modiﬁed (GM) comparator that would give rise to food and feed or environmental
safety concerns. There were no concerns regarding the potential toxicity and allergenicity of the newly
expressed protein AAD-1, and no evidence that the genetic modiﬁcation might signiﬁcantly change the
overall allergenicity of maize DAS-40278-9. The nutritional characteristics of maize DAS-40278-9 are not
expected to differ from those of non-GM maize varieties and no post-market monitoring of food/feed is
considered necessary. Maize DAS-40278-9 is as nutritious as its non-GM comparator and other non-GM
commercial varieties. There are no indications of an increased likelihood of establishment and spread of
occasional feral maize DAS-40278-9 plants, unless these plants are exposed to the intended herbicides.
However, this will not result in different environmental impacts compared to conventional maize.
Considering the scope of the application, interactions with the biotic and abiotic environment were not
considered an issue. Risks associated with the unlikely but theoretically possible horizontal gene transfer
from maize DAS-40278-9 to bacteria were not identiﬁed. The post-market environmental monitoring plan
and reporting intervals are in line with the scope of the application. In conclusion, the EFSA GMO
Panel considers that the information available for maize DAS-40278-9 addresses the scientiﬁc comments
raised by the Member States and that maize DAS-40278-9, as described in this application, is as safe as
the non-GM comparator and non-GM maize reference varieties with respect to potential effects on
human and animal health and the environment in the context of the scope of this application.
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Summary
Following the submission of an application (EFSA-GMO-NL-2010-89) under Regulation (EC)
No 1829/20031 by Dow AgroSciences LLC, the EFSA Panel on Genetically Modiﬁed Organisms (GMO
Panel) was asked to deliver a scientiﬁc opinion on the safety of the herbicide-tolerant genetically
modiﬁed (GM) maize (Zea mays L.) DAS-40278-9 (Unique Identiﬁer DAS-4Ø278-9). The scope of
application EFSA-GMO-NL-2010-89 is for import, processing, and food and feed uses of maize
DAS-40278-9 within the European Union (EU), but excludes cultivation in the EU.
The GMO Panel evaluated maize DAS-40278-9 with reference to the scope and appropriate
principles described in its guidelines for the risk assessment of GM plants. The evaluation addressed
the following components of the risk assessment: the molecular characterisation of the inserted DNA
and analysis of the expression of the corresponding protein; the comparative analyses of
compositional, agronomic and phenotypic characteristics; the safety of the newly expressed proteins
and the whole food/feed with respect to potential toxicity, allergenicity and nutritional characteristics;
the environmental risk assessment and the post-market environmental monitoring plan.
Maize DAS-40278-9 was developed by direct Whiskers-mediated transformation of immature maize
embryos. It expresses the aryloxyalkanoate dioxygenase-1 (AAD-1) protein, which confers tolerance to
2,4-dichlorophenoxyacetic acid (2,4-D) and aryloxyphenoxypropionate (AOPP) herbicides. The
molecular characterisation data established that maize DAS-40278-9 contains one functional insert
consisting of an intact aad-1 expression cassette. No other parts of the plasmid used for
transformation could be detected in maize DAS-40278-9. Bioinformatic analyses and genetic stability
studies were performed and the results did not raise safety issues. The levels of the newly expressed
protein present in maize DAS-40278-9 were obtained and reported adequately.
Based on the agronomic and phenotypic characteristics of maize DAS-40278-9 tested under ﬁeld
conditions, no relevant differences were observed between maize DAS-40278-9 and its non-GM
comparator, except for ‘plant height’ and ‘time to silking’. None of the differences identiﬁed in forage
and grain composition between maize DAS-40278-9 and the non-GM comparator required further
assessment for food and feed safety.
The safety assessment identiﬁed no concerns regarding the potential toxicity of the newly expressed
AAD-1 protein in maize DAS-40278-9, considering the results of a subacute 28-day toxicity study where
no adverse effects were observed at the highest dose tested and considering the results on the
structural and functional properties of the AAD-1 protein, including bioinformatic analyses. The GMO
Panel did not identify indications of safety concerns regarding allergenicity or adjuvanticity with the
AAD-1 protein or regarding the overall allergenicity of maize DAS-40278-9. Based on the comparative
analysis, the nutritional characteristics of food and feed derived from maize DAS-40278-9 are not
expected to differ from that of food and feed derived from non-GM maize varieties. The GMO
Panel concludes that maize DAS-40278-9 is as safe and as nutritious as its non-GM comparator and the
non-GM maize reference varieties. The GMO Panel considers that post-market monitoring of food/feed
derived from maize DAS-40278-9 is not necessary, given the absence of safety concerns identiﬁed.
Due to the low survival capacity of maize, the observed differences in ‘plant height’ and ‘time to
silking’ are unlikely to change the ﬁtness (e.g. survival, fecundity, competitiveness) or invasiveness
characteristics of maize DAS-40278-9 plants. In the case of accidental release into the environment of
viable seeds of maize DAS-40278-9, there are no indications of an increased likelihood of
establishment and spread of feral maize DAS-40278-9 plants, unless these plants are exposed to
2,4-D- or AOPP-containing herbicides. However, the GMO Panel is of the opinion that this will not result
in different environmental impacts compared to conventional maize. Potential interactions with the
biotic and abiotic environment were not considered to be an issue by the GMO Panel. Risks associated
with an unlikely but theoretically possible horizontal gene transfer (HGT) from maize DAS-40278-9 to
bacteria have not been identiﬁed. Therefore, considering the introduced traits, the outcome of the
comparative analysis, the routes of exposure and the limited exposure levels, the GMO Panel concludes
that maize DAS-40278-9 would not raise safety concerns in the event of accidental release of viable
GM maize grains into the environment. The post-market environmental monitoring (PMEM) plan
provided by the applicant is in line with the scope of the application and the requirements of the GMO
Panel for PMEM of GM plants. The GMO Panel agrees with the reporting intervals proposed by the
applicant in the monitoring plan.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
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In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2010-89,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications. In conclusion, the GMO Panel considers that the information available
for maize DAS-40278-9 addresses the scientiﬁc comments raised by the Member States and that maize
DAS-40278-9, as described in this application, is as safe as the non-GM comparator and non-GM maize
reference varieties with respect to potential effects on human and animal health and the environment in
the context of the scope of this application.
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1. Introduction
Maize DAS-40278-9 was developed to confer tolerance to 2,4-dichlorophenoxyacetic acid (2,4-D)
and aryloxyphenoxypropionate (AOPP) herbicides. Tolerance to 2,4-D and AOPP herbicides is achieved
by the expression of an aad-1 gene from Sphingobium herbicidovorans encoding the aryloxyalkanoate
dioxygenase (AAD-1) enzyme.2
1.1. Background
On 11 November 2010, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands an application (Reference EFSA-GMO-NL-2010-89) for authorisation of
genetically modiﬁed (GM) maize DAS-40278-9 (Unique Identiﬁer DAS-4Ø278-9), submitted by Dow
AgroSciences LLC within the framework of Regulation (EC) No 1829/2003 on GM food and feed.
After receiving the application EFSA-GMO-NL-2010-89, and in accordance with Articles 5(2)(b) and 17
(2)(b) of the Regulation (EC) No 1829/2003, EFSA informed the Member States and the European
Commission, and made the summary of the application publicly available on the EFSA website.3 EFSA
initiated a formal review of the application to check compliance with the requirements laid down in Articles
5(3) and 17(3) of the Regulation (EC) No 1829/2003. On 20 January 2011 and 18 February 2011, EFSA
received additional information requested under completeness check (on 20 December 2010 and 9
February 2011, respectively). On 11 March 2011, EFSA declared the application as valid in accordance
with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003.
EFSA made the valid application available to the Member States and the European Commission, and
consulted nominated risk assessment bodies of the Member States, including national Competent
Authorities within the meaning of Directive 2001/18/EC4 following the requirements of Articles 6(4) and
18(4) of Regulation (EC) No 1829/2003, to request their scientiﬁc opinion. The Member States had
3 months after the date of receipt of the valid application (until 11 June 2011) to make their opinion known.
On 20 May 2011, 7 September 2012, 21 May 2014, 19 June 2014, 18 November 2014, 19 February
2015, 27 February 2015, 27 March 2015, 14 April 2015, 24 April 2015, 17 July 2015 and 19 October 2015,
the GMO Panel requested additional information from the applicant. The applicant provided the requested
information on 01 February 2012, 29 January 2014, 23 July 2014, 29 July 2014, 16 December 2014,
12 March 2015, 7 April 2015, 27 April 2015, 1 June 2015, 24 August 2015, 31 March 2016 and 9 August
2016. The applicant also spontaneously provided additional information on 5 April 2011, 11 April 2012,
2 July 2012, 24 August 2012, 29 January 2014, 23 July 2014, 31 March 2016 and 9 August 2016.
In giving its scientiﬁc opinion on maize DAS-40278-9 to the European Commission, the Member States
and the applicant, and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA
has endeavoured to respect a time limit of 6 months from the acknowledgement of the valid application. As
additional information was requested by the EFSA Panel on Genetically Modiﬁed Organisms (GMO Panel),
the time limit of 6 months was extended accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2) of
Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The EFSA GMO Panel was requested to carry out a scientiﬁc assessment of maize DAS-40278-9 for
food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation
(EC) No 1829/2003.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of genetically modiﬁed
organisms (GMOs) or food/feed containing or consisting of GMOs, conditions for the protection of
particular ecosystems/environment and/or geographical areas should be indicated in accordance with
Articles 6(5)(e) and 18(5)(e) of Regulation (EC) No 1829/2003.
2 Dossier: Part I – Section A5.
3 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2010-01326
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
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The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2. Data and methodologies
2.1. Data
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2010-89,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out an evaluation of the scientiﬁc risk assessment of maize DAS-40278-9 for
food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation
(EC) No 1829/2003. The GMO Panel took into account the appropriate principles described in its
guidelines for the risk assessment of GM plants and derived food and feed (EFSA, 2006a; EFSA GMO
Panel, 2011a), the environmental risk assessment (ERA) of GM plants (EFSA GMO Panel, 2010c) and
on the post-market environmental monitoring (PMEM) of GM plants (EFSA, 2006b; EFSA GMO Panel,
2011b).
The comments raised by the Member States are addressed in Annex G of the EFSA overall opinion3
and were taken into consideration during the evaluation of the risk assessment.
3. Assessment
3.1. Molecular characterisation
3.1.1. Evaluation of relevant scientiﬁc data
3.1.1.1. Transformation process and vector constructs
Immature embryos of maize line Hi-II (a derivative of the A188 and B73 inbred maize lines) were
transformed with an FspI fragment of plasmid pDAS1740 by direct Whiskers-mediated transformation
(Petolino et al., 2003; Petolino and Arnold, 2009). The DNA fragment to be transformed was obtained
by a FspI digestion of plasmid pDAS1740, which resulted in ﬁve fragments: a 6,236 bp fragment
containing the aad-1 expression cassette, providing tolerance to 2,4-D and AOPP herbicides, two
fragments containing a portion of the ampicillin resistance gene of the vector backbone (about 1 kb
each), and two minor fragments of 9 bp. Fragments were separated by column chromatography and
the 6,236 bp FspI fragment was isolated and used for transformation.5
The 6,236 bp fragment consisted of the following genetic elements: the constitutive ZmUbi1
promoter from Zea mays; a synthetic, plant codon-optimised version of the aad-1 gene from soil
bacterium S. herbicidovorans; the 30 untranslated region from the peroxidase gene from Z. mays
(ZmPer 30 untranslated region (UTR)), used as a terminator. The expression cassette was ﬂanked by
identical matrix attachment regions (RB7 MAR v3 and RB7 MAR v4) from Nicotiana tabacum, in order
to increase expression of the aad-1 gene.6
Additional functional elements of the FspI digested plasmid pDAS1740, not intended to be
transferred into the maize genome, were plasmid backbone sequences of pUC19, including an
ampicillin resistance gene.
3.1.1.2. Transgene constructs in the GM plant
Molecular characterisation of maize DAS-40278-9 was performed by Southern analysis, polymerase
chain reaction (PCR) and DNA sequence analysis in order to determine insert copy number, size and
organisation of the inserted sequences and to conﬁrm the absence of plasmid backbone sequences.
The approach used was acceptable both in terms of coverage and sensitivity.7
5 Dossier: Part I – Section C1.
6 Dossier: Part I – Section C3.
7 Dossier: Part I – Section D2.
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Southern analysis indicated that maize DAS-40278-9 contains a single insert, which consists of a
single copy of the aad-1 expression cassette from pDAS1740. The insert and copy number were
conﬁrmed by multiple restriction enzyme/probe combinations covering the 6,236 bp inserted fragment
and ﬂanking regions. PCR analyses conﬁrmed the results obtained by Southern analyses. The absence
of vector backbone sequences was demonstrated by Southern analysis using backbone-speciﬁc probes.
The insert and 50 and 30 ﬂanking regions (1,873 and 1,868 bp, respectively) of maize DAS-40278-9
were sequenced. The sequence of the insert conﬁrmed the presence of a 4,816 bp fragment of
pDAS1740 which contains an intact aad-1 expression cassette, a 249 bp partial MAR v3 on the
50 terminus, and a 1,096 bp partial MAR v4 on the 30 terminus. Sequence analysis revealed that the aad-1
sequence in DAS-40278-9 maize is identical to the corresponding sequences in pDAS1740, except for a
single base pair change (from T to C) in the non-coding region of the 30UTR of the aad-1 gene.7
The possible interruption of known endogenous maize genes by the insertion in DAS-40278-9 maize
was evaluated by bioinformatic analyses of the pre-insertion locus and of the genomic sequences
ﬂanking the insert. Comparison of the sequences of the ﬂanking regions in DAS-40278-9 with that of
the pre-insertion locus indicated a 21 bp insertion as well as a 2 bp deletion at the 50 junction in DAS-
40278-9. A 1 bp insertion occurred at the 30 junction.7 The bioinformatic analyses of the DAS-40278-9
ﬂanking regions indicated that the insert in DAS-40278-9 most likely integrated into a region
containing sequences showing similarity to a Grande retrotransposon. No evidence was found for the
interruption of known endogenous gene in the maize genome.8
The results of segregation (see Section 3.1.1.4) and bioinformatic analyses established that the
insert is located in the nuclear genome.9
Updated bioinformatic analyses of the amino acid sequences of the newly expressed protein (AAD-1),
according to EFSA guidance (EFSA GMO Panel, 2011a), did not indicate signiﬁcant similarities to toxins
and allergens.10
In addition, updated bioinformatic analyses of the newly created open reading frames (ORFs) within
the insert and at its junction sites did not indicate signiﬁcant similarities to toxins and allergens.10
3.1.1.3. Information on the expression of the insert
AAD-1 protein levels were analysed by an enzyme-linked immunosorbent assay (ELISA) in material
harvested from replicated ﬁeld trials across eight locations in the USA during the 2009 growing
season.11 Samples analysed included leafs (V2–V4, V9 and R1), roots and pollen (R1), forage (R4),
whole plants (R6), and grain at maturity both those treated and non-treated with quizalofop, 2,4-D or
a combination of the two. The mean values and ranges of the AAD-1 protein levels in grains and
forage are summarised in Table 1.
3.1.1.4. Inheritance and stability of inserted DNA
Genetic stability of the maize DAS-40278-9 insert was assessed by Southern analysis of genomic
DNA from ﬁve different generations.12 The restriction enzyme/probe combinations used were sufﬁcient
Table 1: Protein expression data for AAD-1 in maize DAS-40278-9 (lg/g dry weight) grains and
forage (number of grain and forage samples is 31 for unsprayed and 32 for herbicide-
treated plants)
Untreated 2,4-D-treated Quizalofop-treated 2,4-D- and quizalofop-treated
Grains 3.95(a)  1.03(b)
(1.76–6.31)(c)
4.16  1.22
(1.97–8.18)
4.11  0.55
(2.32–6.15)
3.85  0.95
(1.64–6.46)
Forage 8.08  1.65
(4.63–11.87)
8.74  1.98
(ND–13.73)
8.03  1.76
(4–12.12)
8.55  2.06
(3.77–12.3)
2,4-D: 2,4-dichlorophenoxyacetic acid herbicide.
(a): Mean.
(b): Standard deviation.
(c): Range.
8 Dossier: Part I – Section D7; additional information: 9/8/2016.
9 Dossier: Part I – Section D2, D5; additional information: 9/8/2016.
10 Dossier: Part I – Section D2; additional information: 9/8/2016.
11 Dossier: Part I – Section D3.
12 Dossier: Part I – Section D5.
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to conclude that all the plants tested retained the single copy of the insert and ﬂanking regions, which
were stably inherited in subsequent generations.
Phenotypic stability was observed by segregation analysis of the quizalofop tolerance trait of maize
DAS-40278-9. The results supported the presence of a single insertion, segregating in a Mendelian
fashion.
3.1.2. Conclusion
The molecular characterisation data establish that maize DAS-40278-9 contains a single insert
consisting of one copy of the aad-1 expression cassette. Bioinformatic analyses of the sequences
encoding the newly expressed proteins and other ORFs present within the insert or spanning the
junctions between the insert and genomic DNA did not raise safety issues. The stability of the inserted
DNA and of the introduced herbicide tolerance trait was conﬁrmed over several generations. The levels
of the AAD-1 protein were obtained and reported adequately.
3.2. Comparative analysis
3.2.1. Evaluation of relevant scientiﬁc data
3.2.1.1. Choice of comparator and production of material for the comparative analysis13
Application EFSA-GMO-NL-2010-89 presents data on agronomic and phenotypic characteristics, as
well as forage and grain composition, of maize DAS-40278-9 derived from ﬁeld trials performed at
eight sites in the USA in 2009 (Table 2).
Field trials for the agronomic, phenotypic and compositional assessment of maize DAS-40278-9 were
conducted in major maize growing areas of the USA,14 representing regions of diverse agronomic practices
and environmental conditions. At each site, the following materials were grown in a randomised complete
block design with four replicates: maize DAS-40278-9 not treated with the intended herbicides
(DAS-40278-9/untreated), DAS-40278-9 treated with 2,4-D (DAS-40278-9/2,4-D), DAS-40278-9 treated
with quizalofop (DAS-40278-9/quizalofop), DAS-40278-9 treated sequentially with 2,4-D and quizalofop
(DAS-40278-9/2,4-D+quizalofop), the non-GM comparator (XHH13 9 7SH382), and three commercial
non-GMmaize reference varieties. All materials were treated (sprayed) with requiredmaintenance pesticides
(including conventional herbicides) according to local requirements. In total, six non-GM maize reference
varieties were included across all the ﬁeld trials sites.15 The non-GM comparator XHH13 9 7SH382 had a
genetic background similar tomaize DAS-40278-9 as documented by the pedigree.13
Statistical analysis of ﬁeld trial data
The statistical analysis of the agronomic, phenotypic and compositional data from the 2009 ﬁeld
trials followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010a, 2011a). This
includes, for each of the four treatments of maize DAS-40278-9, the application of a difference test
(between the GM maize and its non-GM comparator) and an equivalence test (between the GM maize
and the set of non-GM commercial reference varieties). The results of the equivalence test are
categorised into four possible outcomes (I–IV, ranging from equivalence to non-equivalence).16
Table 2: Overview of comparative assessment studies with maize DAS-40278-9 provided in
application EFSA-GMO- NL-2010-89
Study focus Study details Comparators
Commercial reference
varieties
Agronomic and phenotypic
characteristics; composition
Field trials, 2009, USA
(eight locations)
Non-GM comparator
(XHH13 9 7SH382)
Six non-GM varieties
Non-GM: non-genetically modiﬁed.
13 Dossier: Part I – Section D7; additional information: 1/2/2012 and 23/7/2014.
14 The sites were in Richland (IA), Carlyle (IL), Bradford (IL), Rockville (IN), La Plata (MO), Dudley (MO), York (NE) and
Germansville (PA).
15 Dekalb 6343, Croplan 691, LG seeds 2597, Northup King 72-G8, Midland/Phillips 7B15 and Pioneer 32T16.
16 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
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3.2.1.2. Agronomic and phenotypic characteristics17
In total, 28 agronomic and phenotypic endpoints were evaluated.18
For 16 agronomic/phenotypic endpoints19 not fulﬁlling the requirements of the statistical tests
described above (e.g. categorical endpoints), a non-parametric test of difference (Wilcoxon signed-rank
test) was performed. No statistically signiﬁcant differences were identiﬁed for any of the endpoints.
Of the 12 endpoints analysed with parametric statistics, the test of equivalence could not be
applied to plant height because of the very small variation among the non-GM reference varieties.
Plant height was found signiﬁcantly different between maize DAS-40278-9 and the non-GM comparator
for one of the four treatments (2,4-D+quizalofop).20
The combination of the test of difference and the test of equivalence could be applied to the
remaining 11 endpoints, with the following results:
• The test of difference between phenotypic and agronomic characteristics of maize DAS-40278-9/
untreated and the non-GM comparator identiﬁed statistically signiﬁcant differences for two
endpoints (early stand count at V1 and time to silking). The test of equivalence between maize
DAS-40278-9/untreated and the non-GM maize reference varieties indicated that early stand
count at V1 fell under equivalence category I and time to silking fell under equivalence category II.
• For DAS-40278-9/2,4-D, statistically signiﬁcant differences were identiﬁed for seven endpoints
(early stand count at V1 and V4, ﬁnal stand count, yield, pollen colour at 30 min, pollen shape
at 30 and 60 min). The test of equivalence showed that all these endpoints fell under
equivalence category I.
• For DAS-40278-9/quizalofop, statistically signiﬁcant differences were identiﬁed for three
endpoints (yield, pollen colour at 30 min, and pollen shape at 60 min). The test of equivalence
showed that all these endpoints fell under equivalence category I.
• For DAS-40278-9/2,4-D+quizalofop, statistically signiﬁcant differences were identiﬁed for ﬁve
endpoints (yield, pollen colour at 30 and 60 min, pollen shape at 30 and 60 min). The test of
equivalence showed that all these endpoints fell under equivalence category I.
Time to silking for DAS-40278-9/untreated was found signiﬁcantly different than the non-GM
comparator and fell under equivalence category II.21 Plant height for DAS-40278-9/2,4-D+quizalofop
was signiﬁcantly different than the non-GM comparator and could not be categorised for equivalence.
The results for time to silking and plant height are further assessed for their potential environmental
impact in Section 3.4.
3.2.1.3. Compositional analysis22
Maize forage and grain harvested from the ﬁeld trials in the USA in 2009 were analysed for 82
compounds (nine compounds for forage23 and 73 compounds for grain24). The compounds included
the key constituents recommended by OECD (2002).
17 Dossier: Part I – Sections D4, D7; additional information: 2/7/2012, 24/8/2012, 29/1/2014, 23/7/2014 and 7/4/2015.
18 Early stand count (V1 and V4), seedling vigour, plant vigour (injury from each of ﬁve herbicide applications), time to silking, time
to pollen shed, pollen viability (pollen shape and colour, both measured at 0, 30, 60 and 120 min), plant height, ear height, stalk
lodging, root lodging, ﬁnal stand count, days to maturity, stay green, disease incidence, insect damage, and yield.
19 Seedling vigour, plant vigour (ﬁve endpoints), pollen shape (0 and 120 min), pollen colour (0 and 120 min), stalk lodging, root
lodging, days to maturity, stay green, disease incidence, and insect damage.
20 Mean values (cm): the non-GM comparator: 280.4; DAS-40278-9/2,4-D+quizalofop: 277.1.
21 Mean values (heat units): non-GM comparator: 1262; DAS-40278-9/untreated: 1270.
22 Dossier: Part I – Section D7; additional information: 1/2/2012, 11/4/2012, 2/7/2012, 24/8/2012, 29/1/2014, 23/7/2014, 12/3/2015
and 7/4/2015.
23 Proximates (crude protein, total fat, ash and moisture), carbohydrates by calculation, ﬁbre fractions (acid detergent ﬁbre
(ADF) and neutral detergent ﬁbre (NDF)), calcium and phosphorus.
24 Proximates (crude protein, total fat, ash, and moisture), ﬁbre fractions (ADF, NDF and total dietary ﬁbre), amino acids (alanine,
arginine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline,
serine, threonine, tryptophan, tyrosine and valine), fatty acids (caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0),
myristic acid (C14:0), myristoleic acid (C14:1), pentadecanoic acid (C15:0), pentadecenoic acid (C15:1), palmitic acid (C16:0),
palmitoleic acid (C16:1), heptadecanoic acid (C17:0), heptadecenoic acid (C17:1), stearic acid (C18:0), oleic acid (C18:1), linoleic
acid (C18:2), linolenic acid (C18:3), c-linolenic acid (C18:3), arachidic acid (C20:0), eicosenoic acid (C20:1), eicosadienoic acid
(C20:2), eicosatrienoic acid (C20:3), arachidonic acid (C20:4) and behenic acid (C22:0).), 10 minerals (calcium, phosphorous,
potassium, sodium, iron, copper, magnesium, manganese, selenium and zinc), eight vitamins (vitamin B1 (thiamine), vitamin B2
(riboﬂavin) vitamin B3 (niacine), vitamin B6 (pyridoxine), vitamin B9 (folic acid), b-carotene, vitamin C and vitamin E), and other
compounds (inositol, furfural, p-coumaric acid, ferulic acid, phytic acid, trypsin inhibitor and rafﬁnose).
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The GMO Panel considered the studies performed by the applicant concerning the substrate
speciﬁcity of the newly expressed protein AAD-1, which showed that AAD-1 appears to be capable
of oxidising the maize endogenous compounds trans-cinnamic acid and indole-3-acetic acid.25 The
GMO Panel noted that phenylalanine and coumaric acid, involved in the phenylpropanoid biosynthesis
and metabolically related to trans-cinnamic acid, were included in the spectrum of compositional
parameters.
Seventeen grain constituents26 with more than 50% of the observations below the limit of
quantiﬁcation were excluded from the statistical analysis.
Of the remaining 65 compounds, the test of equivalence could not be applied to one forage
constituent (total fat) and to ﬁve grain constituents27 because of the very small variation among the
non-GM reference varieties. Among those six constituents, arginine content was found signiﬁcantly
different than the non-GM comparator (Table 3).
For the remaining 59 endpoints, the results of the difference and equivalence tests were as follows:
• The test of difference between maize DAS-40278-9/untreated and the non-GM comparator
identiﬁed statistically signiﬁcant differences for 20 constituents28 (16 in grain and four in
Table 3: Compositional endpoints that are further considered based on the results of the statistical
analysis: means (for the GM maize and the non-GM comparator) and equivalence limits
(from the non-GM reference varieties) estimated from ﬁeld trials data (USA 2009, Table 2)
Endpoint
Non-GM
comparator
XHH13 3
7SH382
Maize DAS-40278-9 Equivalence
limits from
non-GM
reference
varieties
Untreated(a) 2,4-D(b) Quizalofop(c)
2,4-D+
quizalofop(d)
Glycine
(% AA)
3.67 3.52* 3.55* 3.48* 3.51* (3.54, 4.06)
Leucine
(% AA)
13.06 13.34* 13.26* 13.40* 13.32* (12.18, 13.33)
Methionine
(% AA)
1.81 1.78 1.77 1.74* 1.75 (1.77, 2.2)
Phenylalanine
(% AA)
5.35 5.40 5.43* 5.44* 5.41 (4.98, 5.32)
Carbohydrates
(% DM)
83.65 82.91* 82.8* 82.74* 82.91* (83, 86.75)
Crude protein
(% DM)
10.85 11.56* 11.67* 11.69* 11.51* (8.99, 11.23)
b-Carotene
(mg/kg DM)
2.46 2.80* 2.88* 2.95* 2.80* (0.61, 1.48)
Arginine
(% AA)
4.64 4.47* 4.51* 4.4* 4.48* –
For the GM maize, signiﬁcantly different entries are marked with an asterisk, while the outcomes of the test of equivalence are
differentiated by greyscale backgrounds: white (for equivalence categories I–II and for arginine, for which the test was not
performed), light grey (equivalence category III) and dark grey (equivalence category IV).
% AA: percentage total amino acids; DM: dry matter; –: the test of equivalence was not applied because of the small variation
among the non-GM reference varieties.
(a): maize DAS-40278-9 given no target herbicide treatment.
(b): maize DAS-40278-9 treated with 2,4-D.
(c): maize DAS-40278-9 treated with quizalofop.
(d): maize DAS-40278-9 treated sequentially with 2,4-D and quizalofop.
25 Dossier: Part I – Section D7.8.1; additional information: 1/2/2012 and 1/6/2015.
26 Caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), myristic acid (C14:0), myristoleic acid (C14:1), pentadecanoic
acid (C15:0), pentadecenoic acid (C15:1), palmitoleic acid (C16:1), heptadecanoic acid (C17:0), heptadecenoic acid (C17:1),
gamma-linolenic acid (C18:3), eicosadienoic acid (C20:2), eicosatrienoic acid (C20:3), arachidonic acid (C20:4) and behenic
acid (C22:0), sodium and furfural.
27 Inositol, phytic acid, ash, selenium and arginine.
28 Forage: carbohydrates, crude protein, calcium and phosphorus; grain: carbohydrates, crude protein, aspartic acid, glutamic
acid, glycine, leucine, proline, threonine, valine, trypsin inhibitor, stearic acid (C18:0), moisture, calcium, niacin, b-carotene
and ascorbic acid.
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forage). The test of equivalence between maize DAS-40278-9/untreated and the set of
non-GM maize reference varieties indicated that the level of 15 of the 20 constituents fell
under equivalence category I or II, while the level of ﬁve grain constituents fell under
equivalence category III or IV (Table 3).
• For DAS-40278-9/2,4-D, statistically signiﬁcant differences were identiﬁed for 20 constituents29
(16 in grain and four in forage). The test of equivalence showed that the level of 16 of the 20
constituents fell under equivalence category I or II, while the level of four grain constituents
fell under equivalence category III or IV (Table 3).
• For DAS-40278-9/quizalofop, statistically signiﬁcant differences were identiﬁed for 26
constituents30 (21 in grain and ﬁve in forage). The test of equivalence showed that the level of
19 of the 26 constituents fell under equivalence category I or II, while the level of seven grain
constituents fell under equivalence category III or IV (Table 3).
• For DAS-40278-9/2,4-D+quizalofop, statistically signiﬁcant differences were identiﬁed for 14
constituents31 (11 in grain and three in forage). The test of equivalence showed that the level
of 10 of the 14 constituents fell under equivalence category I or II, while the level of four grain
constituents fell under equivalence category III or IV (Table 3).
The GMO Panel considered the results for the two compounds metabolically related to trans-
cinnamic acid; no differences were identiﬁed for coumaric acid, and the difference identiﬁed for
phenylalanine (Table 3) does not pose a safety concern. Therefore, it is unlikely that the AAD-1
enzyme interacts with endogenous plant metabolism in a way which may pose a safety concern.
The GMO Panel assessed all the compositional differences between maize DAS-40278-9 and the
non-GM comparator. After considering the biological role of the compounds and the magnitude and
direction of the changes observed, the GMO Panel did not identify any need for further assessment
with regard to food and feed safety.
3.2.2. Conclusion
The GMO Panel concludes that none of the differences identiﬁed in grain and forage composition
between maize DAS-40278-9 and the non-GM comparator, and none of those identiﬁed in the
agronomic and phenotypic characteristics, needs further assessment regarding food and feed safety.
Based on the agronomic and phenotypic characteristics of maize DAS-40278-9 tested under ﬁeld
conditions, none of the differences identiﬁed between maize DAS-40278-9 and the non-GM comparator
are considered relevant except for plant height and time to silking, which are further assessed for their
potential environmental impact in Section 3.4.
3.3. Food/feed safety assessment
3.3.1. Evaluation of relevant scientiﬁc data
3.3.1.1. Effects of processing32
Processed products
Based on the outcome of the comparative assessment (Section 3.2), processing of maize
DAS-40278-9 into food and feed products is not expected to result in products different from those of
commercial non-GM maize varieties.
Newly expressed proteins33
a) Effect of temperature on AAD-1 protein. The thermal stability of the bacterial AAD-1 protein was
evaluated by heating protein solutions for 30 min at 50, 70 and 95°C in a buffer solution. At all heating
29 Forage: carbohydrates, crude protein, calcium and phosphorus; grain: carbohydrates, crude protein, glycine, leucine,
phenylalanine, threonine, rafﬁnose, stearic acid (C18:0), arachidic acid (C20:0), moisture, calcium, iron, phosphorus, niacin,
b-carotene and ascorbic acid.
30 Forage: ash, carbohydrates, crude protein, calcium and phosphorus; grain: carbohydrates, crude protein, alanine, cystine,
glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, threonine, tryptophan, valine, trypsin inhibitor, stearic acid
(C18:0), calcium, phosphorus, zinc, niacin, b-carotene and ascorbic acid.
31 Forage: carbohydrates, crude protein and phosphorus; grain: carbohydrates, crude protein, aspartic acid, glycine, leucine,
threonine, stearic acid (18:0), moisture, calcium, b-carotene and niacin.
32 Dossier: Part I – Section D7.6.
33 Dossier: Part I – Section D7.8.1; additional Information: 23/7/2014 and 27/4/2015.
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conditions, the enzymatic activity of the protein was reduced to less than 3%. Only 1% of its
immunoreactivity, as measured by a polyclonal antibody sandwich ELISA, was still observed at the
temperatures tested. The molecular mass of the AAD-1 protein was unchanged, as indicated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
b) Effect of pH on the AAD-1 protein. The effect of pH on the bacterial AAD-1 protein in vitro
activity was determined using 2,4-D as a substrate, revealing a pH optimum of 7.9 with progressive
loss of activity at decreasing and increasing pH values. SDS-PAGE indicated that the AAD-1 protein
concentration remained consistent over this pH range, suggesting that loss of enzymatic activity
resulted from disruption of enzyme structure and not degradation of the AAD-1 protein.
3.3.1.2. Toxicology
Maize DAS-40278-9 expresses the new protein AAD-1 (Section 3.1.1).
Proteins used for safety assessment
Given the technical restraints in producing large enough protein quantities for safety testing from
plants, AAD-1 protein was recombinantly produced in Pseudomonas ﬂuorescens. The puriﬁed protein
from the bacterial source and from maize DAS-40278-9 were characterised and compared in terms of
their physicochemical, structural and functional properties.
AAD-1 characterisation and equivalence34
SDS-PAGE showed that both plant- and microbe-derived AAD-1 proteins migrated close to the
expected molecular weight of ~ 33 kDa and were comparably immunoreactive to AAD-1 protein
speciﬁc antibodies as shown by western blot analysis. In addition, glycosylation detection analysis
demonstrated that the plant- and microbe-derived AAD-1 proteins were not glycosylated. Amino acid
sequence analysis by matrix-assisted laser desorption/ionisation time-of-ﬂight mass spectrometry
(MALDI-TOF MS) and electrospray ionisation liquid chromatography/mass spectrometry (ESI-LC/MS)
showed that both proteins matched the expected AAD-1 sequence. These data also revealed that the
N-terminal methionine of both proteins was truncated. Additional variants were observed for the plant
protein with another three short truncations up to alanine 4. A small portion of the plant protein (3%)
was also N-acetylated. The C-termini were identical for both proteins and fully matched the theoretical
AAD-1 sequence. Functional equivalence was demonstrated by a biochemical in vitro activity assay
which showed that both proteins had comparable activity and speciﬁcity for the intended herbicides.
Furthermore, the microbial AAD-1 protein was screened for its ability to utilise certain endogenous
plant substrates. The data demonstrated that AAD-1 activity is unlikely to have a metabolic impact
within transgenic plants. In addition, to justify the appropriateness of the microbial recombinant AAD-1
protein used in a 28-day oral toxicity study in mice,35 equivalence with the DAS-40278-9 expressed
AAD-1 protein was demonstrated by MS analysis and enzymatic activity assay.
Based on these data, the GMO Panel accepts the use of the microbial recombinant AAD-1 proteins
for the safety studies.
Toxicological assessment of newly expressed protein
The AAD-1 protein has never been assessed by the GMO Panel.
a) Bioinfomatic studies36
Bioinformatic analyses of the amino acid sequence of the AAD-1 protein expressed in maize
DAS-40278-9 revealed no relevant similarities to proteins known to be toxic to humans and animals
(Section 3.1.1.2).
b) In vitro degradation studies37
The resistance to degradation by pepsin of the bacterial AAD-1 protein was investigated in solutions at
pH ~ 1.2. The integrity of the test protein in probes taken at various time points was analysed by SDS-PAGE
followed by protein staining or western blot. The AAD-1 protein was degraded by pepsin within 30 sec.
34 Dossier: Part I – Section D7.8.1; additional information: 1/2/2012, 1/6/2015 and 9/8/2016.
35 Additional information: 9/8/2016.
36 Dossier: Part I – Section D7.8.1; additional information: 29/1/2014.
37 Dossier: Part I – Section D7.9.1; additional information: 29/7/2014.
Scientiﬁc opinion on genetically modiﬁed maize DAS-40278-9
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2016;14(12):4633
c) Acute oral toxicity testing38
The bacterial-derived AAD-1 protein was administrated by oral gavage at a dose of 2,000 mg/kg
body weight (bw) to male and female Crl:CD1(ICR) mice. No effects related to the AAD-1 protein were
observed.
The GMO Panel is of the opinion that acute toxicity testing of the newly expressed proteins is of
little additional value for the risk assessment of the repeated consumption of food and feed from GM
plants by humans and animals.
d) 28-day repeated dose toxicity studies39
The applicant provided a 28-day oral repeated dose toxicity study in mice to investigate the
potential toxicity of the AAD-1 protein. However, the GMO Panel did not consider the overall study
design adequate to identify the potential hazard of the AAD-1 protein, because of the low doses of
AAD-1 protein tested (highest dose level approximately 45 mg/kg bw per day) and the limited number
of animals used in treatment groups (5 per sex per group) to ensure an adequate statistical power
(EFSA GMO Panel, 2011a). Moreover, the GMO Panel noted that analyses of coagulation were not
performed. The GMO panel requested a 28-day toxicity study in rodents, to support the safety
assessment of the AAD-1 protein, with a sufﬁcient number of animals, selecting the doses according to
the OECD TG 407 in order to induce adverse effects at the highest dose, or following a limit test
approach, if toxicity is not expected.
Following the EFSA request, the applicant provided a new 28-day oral repeated dose toxicity study
in mice, conducted in accordance with the OECD TG 407 and in compliance with the principles of Good
Laboratory Practice (GLP). Groups of singly caged Crl:CD1(ICR) mice (12 per sex per group) were
administered by gavage the AAD-1 protein, at a targeted dose of 1,000 mg/kg bw per day (AAD-1
protein group); the vehicle alone (vehicle control group) and bovine serum albumin (BSA) at a
targeted nominal dose of 1,000 mg/kg bw per day (BSA control group). The ADD-1 and BSA protein
formulations were prepared daily; for the AAD-1 protein group, the concentration of the AAD-1 protein
in the test material (63.5%) was taken into account to meet the targeted dose. Feed and water were
provided ad libitum. Animals were checked daily for mortality and general clinical signs; detailed clinical
observations were conducted on all animals pretreatment and then weekly. Ophthalmoscopy was
carried out before the start and at the end of the treatments. Body weights were recorded on test day
1, 2, 3, 4, 8, 15, 22 and 29 (terminal body weight) and body weight gains were calculated relative to
test day 1. Feed consumption was determined on test days 1–2, 2–3, 3–4, 4–8, 8–15 and 22–29. At
the end of the treatment period, haematological and clinical chemistry analyses were performed. All
animals were sacriﬁced and underwent a complete necropsy examination with selected organs
weighed. Organs and tissues from all animals were subjected to a comprehensive histological
examination.
The GMO Panel noted that the AAD-1 protein formulations were prepared from the powdered test
material stored at approximately 4°C until use. Stability tests on the powdered test material (i.e. the
lyophilized AAD-1 protein) were not performed as part of this study and, according to the study report,
the test material stability under storage conditions was unknown. Therefore, the concentration of
AAD-1 protein of 63.5% in the powdered test material following storage has not been conﬁrmed.
The GMO Panel noted that haematology and clinical chemistry analyses were conducted on six
mice/gender per group and coagulation (prothrombin time) was conducted on the remaining six
animals in each group. The reasoning provided by the applicant was practical limitations in obtaining
sufﬁcient quantities of blood from mice for both haematology, clinical chemistry and coagulation
examinations in the same animal. However, it is well known that when mice are used as the test
animal, additional animals may be needed in each dose group, to conduct all required determinations.
The GMO Panel also noted that the animals were not fasted prior to necropsy and blood collection, as
recommended in the OECD TG 407.
The AAD-1 protein group was statistically compared to the BSA control group; the latter was also
compared to the vehicle control group in order to assess potential effects of the higher protein intake.
All the parameters examined statistically were ﬁrst tested for equality of variance using Bartlett’s test
(for sexes combined), and possibly scale-transformed if the test was signiﬁcant.40 Two different
statistical analyses were then performed: a two-way analysis of variance (ANOVA; factors: sex and
38 Dossier: Part I – Section D7.8.1.
39 Dossier: Part I – Section D7.8.1; additional information: 9/8/2016.
40 a = 0.01.
Scientiﬁc opinion on genetically modiﬁed maize DAS-40278-9
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2016;14(12):4633
dose for the sexes combined), followed by a one-way ANOVA (factor: dose for sexes separated) if a
signiﬁcant result41 was obtained in the former. The same parameters were also tested using Bartlett’s
test (for sexes separated) and analysed with a one-way ANOVA (factor: dose for sexes separated).
Comparisons of individual dose groups to the control group were made with Dunnett’s test.41 For body
weight gains, globulin, albumin/globulin ratio, RBC indices and differential WBC counts, only descriptive
statistics were reported.
The results of the dose conﬁrmation analyses from the ﬁrst mix revealed that the average
recoveries for AAD-1 protein and BSA in 0.5% METHOCEL were 75.1% and 79.4%, respectively, based
on nominal dosing suspensions at 100 mg/mL; the average recoveries were therefore within the
acceptable experimental variation (70–120%). The GMO Panel noted that, based on the measured
concentration of AAD-1 protein in the dosing suspension, the actual dose administered in the ﬁrst mix
was 751 mg/kg bw per day. The results of the homogeneity analyses indicated that the preparations
were homogeneously mixed.
The few statistically signiﬁcant differences between the BSA control and vehicle control groups in
the examined parameters were considered by the GMO Panel to be within normal biological variability;
therefore, both the vehicle control and the BSA control groups were considered suitable to be used as
the control groups for the comparison and evaluation of data from the AAD-1 protein group.
No AAD-1 protein-related mortality, clinically relevant ﬁndings and ophthalmic changes were found.
No statistically signiﬁcant differences in body weight or body weight gain were observed in the AAD-1
protein group compared to the BSA control group. Statistically signiﬁcantly lower feed consumption
(day 4–8) was observed in females of the AAD-1 protein group when compared with the BSA control
group. This difference was considered by the GMO Panel to be an incidental ﬁnding as being transient,
only observed in one gender and not associated with signiﬁcant differences in body weights and body
weight gains.
Haematology analysis showed statistically signiﬁcantly lower haemoglobin (Hb) levels in males of
the AAD-1 protein group when compared with the BSA control group. The difference was small; the
mean level was very close to the mean level in the vehicle control group and fell within the historical
control range. In the absence of changes in other haematological parameters, the GMO
Panel considered that this difference was not toxicologically relevant.
Clinical chemistry analysis showed a statistically signiﬁcantly higher serum alkaline phosphatase
(ALP) activity in males of the AAD-1 protein group when compared with the BSA control group. The
GMO Panel noted that the activities in individual animals varied considerably in all three groups and the
mean value was close to the historical control range.42 Therefore, this difference was not considered
to be toxicologically relevant.
There were no other signiﬁcant differences in haematological and clinical chemistry parameters,
and in the prothrombin time. However, the GMO Panel noted that the haematological, clinical
chemistry and coagulation examinations were only performed on six animals per gender per group,
and thus, the EFSA recommendation to use a higher number of animals was not fulﬁlled for the
examination of these parameters.
Organ weight determinations showed no statistically signiﬁcant differences, except for a higher
absolute and relative prostate weight in males treated with the AAD-1 protein compared with the BSA
control group. The mean values of the absolute and relative prostate weights were very close to the
historical control ranges; the differences were not associated with macroscopic and/or microscopic
ﬁndings in the prostate gland or with changes in other organs and tissues of the male genital system.
Therefore, the GMO Panel considered that the differences were not toxicologically relevant.
Macroscopic examinations at necropsy revealed no gross pathological ﬁndings related to the
treatment with the AAD-1 protein. Microscopic examinations of selected organs and tissues identiﬁed
no treatment-related differences in the incidence and severity of the histopathological ﬁndings
between the groups.
The GMO Panel concluded that there were no adverse effects after a 28 day administration of the
AAD-1 protein to mice at the dose tested (751 mg/kg bw per day). However, the GMO Panel noted
that the haematological, clinical chemistry and coagulation examinations were only performed on 6
animals per gender per group, and thus, the EFSA recommendation to use a higher number of animals
was not fulﬁlled for the examination of these parameters.
41 a = 0.05.
42 Historical control mean values were obtained from six 28-day mouse studies between 2012 and 2016, as stated in the study
report.
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Toxicological assessment of components other than newly expressed proteins
No new constituents other than AAD-1 protein are expressed in maize DAS-40278-9 and no
relevant changes in the composition of GM maize were detected in the comparative compositional
analysis (see Section 3.2.1.3).
3.3.1.3. Animal studies with the food/feed derived from GM plants
None of the observed differences in the composition of the food/feed derived from maize
DAS-40278-9 (Section 3.2.1.3) required further assessment regarding food and feed safety. Therefore,
no animal studies on the food/feed derived from maize DAS-40278-9 were required (EFSA, 2006a;
EFSA GMO Panel, 2011a). However, the applicant provided a broiler study which was considered by
the EFSA GMO Panel.
A 42-day feeding study with a total of 600 chickens (half male and half female) for fattening
(day-old Ross 708) was provided.43 The birds were randomly allocated to ﬁve dietary treatment groups
with 120 chicks per treatment (six pens/treatment per gender, 10 birds per pen). Birds were fed diets
containing maize DAS-40278-9 (AAD-1 veriﬁed by ELISA), and compared to those fed diets containing
the non-GM comparator or three non-GM commercial maize varieties (Dekalb 6343, NK 72-G8 and
Pioneer 32T16 maize). Maize DAS-40278-9 was not treated with intended herbicides. The starter
(0–14 days), grower (15–28 days) and ﬁnisher (29–42 days) diets consisted of 50%, 55% and 60%
maize meal, respectively. Other component was a commercial soybean meal (46% protein). Before
feed formulation, all maize and soybean meal varieties were analysed for proximates, ADF, NDF,
minerals, amino acids, fatty acids, some anti-nutrients and mycotoxins. The diets were isonitrogenous
and isocaloric (conﬁrmed by analysis). The AAD-1 protein was present throughout the study, and at
the end of the study it was reduced approximately to 30% of AAD-1.44 Feed in mash form and water
were provided ad libitum.
Chickens were observed twice daily for mortality and clinical signs; deaths were recorded and
necropsy performed on all birds found dead. Pen body weights and feed intake were measured on day
1, 14, 28 and 42 and feed conversion ratio was calculated. At the end of the trial, four birds per pen
were taken for carcass evaluation (yield, dressing percentage, weight of thighs, breast, wings, legs,
abdominal fat and whole liver). ANOVA (pen was considered as the experimental unit, dietary
treatment and gender as ﬁxed effects) was applied to determine statistical differences between
groups. Four pair-wise comparisons between the GM group and each of the non-GM groups were
made by Dunnett’s test.
Overall mortality was low (< 2%) with no signiﬁcant differences between the groups. No signiﬁcant
treatment-by-sex interactions were detected for ﬁnal weight, weight gain and feed intake. Overall, no
signiﬁcant differences were found in ﬁnal body weight, feed intake, and feed to gain ratio between the
treatment groups. Final body weight was higher in males (average ca 2.8 kg) than females (average
ca 2.5 kg). Feed to gain ratio was similar (average 1.65 for females and 1.61 for males). Carcass
characteristics and liver weight did not show signiﬁcant differences between animals fed diets
containing the GM and the non-GM comparator.
The GMO Panel concludes that administration of diets containing up to 60% of maize meal
DAS-40278-9 to broilers, up to 42 days, did not cause adverse effects. Moreover, the measured
performance endpoints were similar between groups fed balanced diets containing GM and non-GM
maize.
3.3.1.4. Allergenicity45
The strategies to assess the potential risk of allergenicity focus on the source of the recombinant
protein, the potential of the newly expressed protein to induce sensitisation or to elicit allergic
reactions in already sensitised persons and on whether the transformation may have altered the
allergenic properties of the modiﬁed plant.
43 Dossier: Part I – Section D7.8.4.
44 AAD-1 protein mean concentration in the meal was 3.59 mg/kg fresh weight; at the beginning of the experiment, the diets
contained 2.12, 2.77 and 2.70 mg/kg fresh weight; at the end of the study, the diets contained 0.52, 1.11 and 0.7 mg/kg
fresh weight (starter, grower and ﬁnisher, respectively).
45 Dossier: Part I – Section D7.9; additional information: 29/1/14, 16/12/2014 and 9/8/2016.
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Assessment of allergenicity of the newly expressed proteins46
A weight-of-evidence approach was followed, taking into account all of the information obtained on
the newly expressed protein, since no single piece of information or experimental method yield
sufﬁcient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA GMO Panel, 2010b, 2011a).
The aad-1 gene originates from S. herbicidovorans, a soil microorganism which is not considered to
be a common allergenic source.
Updated bioinformatic analyses of the amino acid sequences of the AAD-1 protein, using the
criterion of 35% identity in a window of 80 amino acids, revealed no signiﬁcant similarities to known
allergens. In addition, the applicant also performed analyses searching for matches of eight contiguous
identical amino acid sequences between the AAD-1 protein and known allergens, which conﬁrmed the
outcome of the previous bioinformatic analyses.
The study on resistance to degradation of the AAD-1 protein by proteolytic enzymes has been
described in Section 3.3.1.2.
There is no information available on the structure or function of the newly expressed AAD-1 protein
that would suggest an adjuvant effect resulting in or increasing an eventual immunoglobulin E (IgE)
response to a bystander protein.
In the context of the present application, the GMO Panel considers that there are no indications
that the newly expressed AAD-1 protein in maize DAS-40278-9 may be allergenic.
Assessment of allergenicity of GM food/feed47
To date, maize has not been considered to be a common allergenic food48 (OECD, 2002), and
therefore, the GMO Panel did not request experimental data to analyse the allergen repertoire of GM
maize. The GMO Panel regularly reviews the available publications on food allergy to maize.
In the context of the present application and considering the data from the molecular
characterisation, the compositional analysis and the assessment of the newly expressed protein
(Sections 3.1, 3.2 and 3.3), the GMO Panel identiﬁed no indications of a potentially increased
allergenicity of maize DAS-40278-9 food and feed with respect to food and feed from the non-GM
comparator.
3.3.1.5. Nutritional assessment of GM food/feed
The intended trait of maize DAS-40278-9 is herbicide tolerance, with no intention to alter the
nutritional parameters. The outcome of the compositional analysis of maize DAS-40278-9 did not
identify differences that would require a nutritional assessment as regards food and feed
(Section 3.2.1.3). The introduction of food and feed products derived from maize DAS-40278-9 into
the food and feed supply is expected to have no adverse nutritional impact, as compared to the
non-GM comparator and commercial reference varieties.
3.3.1.6. Post-market monitoring of GM food/feed
There was no indication that maize DAS-40278-9 is any less safe than the non-GM comparator.
Maize DAS-40278-9 is as nutritious as non-GM commercial varieties. Therefore, and in line with the
guidance documents (EFSA, 2006a; EFSA GMO Panel 2011a), the GMO Panel is of the opinion that
post-market monitoring of the GM food/feed is not necessary.
3.3.2. Conclusion
The safety assessment identiﬁed no concerns regarding the potential toxicity of the newly
expressed AAD-1 protein in maize DAS-40278-9, considering the results of a subacute 28-day toxicity
study where no adverse effects were observed at the highest dose tested and considering the results
on the structural and functional properties of the AAD-1 protein, including bioinformatic analyses. The
GMO Panel did not identify indications of safety concerns regarding allergenicity or adjuvanticity with
the AAD-1 protein or regarding the overall allergenicity of maize DAS-40278-9. Based on the
comparative analysis, the nutritional characteristics of food and feed derived from maize DAS-40278-9
are not expected to differ from that of food and feed derived from non-GM maize varieties.
46 Dossier: Part I – Section D7.9.1; additional information: 29/1/14, 16/12/2014 and 9/8/2016.
47 Dossier: Part I – Section D7.9.2.
48 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to Directive
2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ L 310, 27.11.2007, p. 11–14.
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3.4. Environmental risk assessment and monitoring plan
3.4.1. Evaluation of relevant scientiﬁc data
Considering the scope of application EFSA-GMO-NL-2010-89 (which excludes cultivation), the ERA
of maize DAS-40278-9 is mainly concerned with: (1) the exposure of bacteria to recombinant DNA in
the gastrointestinal tract of animals fed GM material and bacteria present in environments exposed to
their faecal material (manure and faeces); and (2) the accidental release into the environment of
viable maize DAS-40278-9 grains during transportation and processing.
3.4.1.1. Environmental risk assessment
Persistence and invasiveness of the GM plant49
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional maize plants may occur
outside cultivation areas but survival is limited mainly by a combination of low competitiveness, the
absence of a dormancy phase and susceptibility to plant pathogens, herbivores and cold climate
conditions (OECD, 2002). In ﬁelds, maize volunteers may arise under some environmental conditions
(mild winters). Observations done in the ﬁeld during harvesting indicate that grain may survive and
overwinter in some regions, resulting in volunteers in subsequent crops. The occurrence of maize
volunteers has been reported in Spain and other European regions (e.g. Gruber et al., 2008). However,
maize volunteers have been shown to grow weakly and ﬂower asynchronously with the maize crop
(Palaudelmas et al., 2009).
As mentioned in Section 3.2.1.3, phenotypic and agronomic characteristics of maize DAS-40278-9
were evaluated in a ﬁeld trial across eight locations in the USA in 2009. Maize DAS-40278-9 was
considered equivalent to the non-GM maize reference varieties for eight out of the ten endpoints for
which a signiﬁcant difference was observed between the GM maize and its comparator. For the
remaining two endpoints (i.e. ‘plant height’ and ‘time to silking’), the equivalence test could not be
performed for ‘plant height’ because of lack of variation in the commercial non-GM maize reference
varieties, and the ‘time to silking’ of maize DAS-40278-9 fell under equivalence category II
(i.e. equivalent to the non-GM maize reference varieties more likely than not).
The difference observed for ‘plant height’ between maize DAS-40278-9/2,4-D+quizalofop and its
non-GM comparator was considered not relevant in terms of increased ﬁtness potential given its nature
and magnitude.
The equivalence test for the endpoint ‘time to silking’ indicates that equivalence with non-GM
reference varieties is more likely than non-equivalence. For the correlated endpoints that are likely to
indicate a change in ﬁtness potential of the GM maize, such as, for example, yield, equivalence with
non-GM reference varieties was demonstrated. The observed difference in ‘time to silking’ might
therefore be an indication of unintended effects due to the genetic modiﬁcation. Differences in seed lot
quality could also explain such observations; however, the information included in the dossier does not
indicate such an effect.
In the case of accidental release into the environment of maize DAS-40278-9, there are no indications
of an increased likelihood of establishment and spread of occasional feral maize DAS-40278-9 plants.
Should these plants be exposed to 2,4-D- or AOPP-containing herbicides, they are likely to exhibit a
selective advantage that could increase their transient local occurrence. However, this will not result in
different environmental impacts compared to conventional maize.
In addition to the data presented by the applicant, the GMO Panel is not aware of any scientiﬁc
report of increased spread, establishment and survival capacity of maize DAS-40278-9 or maize with
comparable properties.
Therefore, the GMO Panel concludes that it is unlikely that maize DAS-40278-9 would differ from
conventional maize varieties in its ability to survive until subsequent season under European
environmental conditions, if there was accidental release of viable GM maize grains into the
environment. The occurrence of GM maize plants in the environment will thus be limited.
49 Dossier: Part I – Section D4, D9.1 and D9.2.
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Effects of gene transfer50
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through horizontal gene transfer (HGT) of DNA or vertical gene transfer via seed
spillage followed by cross-pollination.
1) Plant-to-bacteria gene transfer
Genomic DNA is a component of many food and feed products derived from maize. It is well
documented that DNA present in food and feed becomes substantially degraded during processing and
digestion in the human or animal gastrointestinal tract. However, a low level of exposure of fragments of
ingested DNA, including the recombinant fraction of such DNA, to bacteria in the digestive tract of humans,
domesticated animals, and other environments exposed to the GM plant or plant material is expected.
Current scientiﬁc knowledge of recombination processes in bacteria suggests that horizontal
transfer of non-mobile, chromosomally located DNA fragments between unrelated organisms (such as
from plants to bacteria) is not likely to occur at detectable frequencies under natural conditions
(for further details see EFSA, 2009).
A successful HGT would require stable insertion of the recombinant DNA sequences into a bacterial
genome and a selective advantage to be conferred to the transformed host. The only mechanism
known to facilitate horizontal transfer of non-mobile, chromosomal DNA fragments to bacterial
genomes, is homologous recombination. This requires the presence of stretches of DNA sequences
that are similar in the recombining DNA molecules. The similarity between the plant and bacterial
sequences can be situated in the coding region of a recombinant protein (transgene) or in the border
regions of the recombinant gene cassettes inserted into the plant genome. In the case of sequence
identity with the transgene itself, recombination would result in gene replacement. In the case of
identity with border regions, recombination could result in the insertion of additional DNA sequences in
bacteria and thus confer the potential for new properties.
The coding sequence of the AAD-1 protein, as inserted in maize DAS-40278-9, is a synthetic gene
derived from the aad-1 gene of S. herbicidovorans, but codon-optimised with a higher G+C level for
better expression in plant cells. None of the genetic elements of the DAS-40278-9 insert is of bacterial
origin. S. herbicidovorans and other closely related bacteria have been isolated for their capacity to
degrade 2,4-D or related compounds by dioxygenase activities (Horvath et al., 1990). Their occurrence
in the main receiving environments, i.e. the gastrointestinal tract of humans or animals, is expected to
be low or non-existent. However, occurrence of the recombinant genes outside their immediate
receiving environment (e.g. through manure and faeces) in habitats of S. herbicidovorans and related
bacteria is therefore also considered here.
On a theoretical basis (i.e. without any study providing experimental evidence for the occurrence of
HGT in the case of GM food and feed derived from maize DAS-40278-9 or any other GM plant), and
provided that plant codon optimisation would not strongly decrease the DNA sequence identity of the
aad-1 gene to corresponding sequences in bacteria, it can be assumed that, as an extremely rare
event, homologous recombination may occur which would transfer the aad-1 gene of maize
DAS-40278-9 to bacteria in the environment. Such recombination event would be substitutive,
replacing natural variants of the aad-1 gene and, thus, not confer a novel trait. Such transfer would
unlikely provide a new selective advantage for recipient bacteria (EFSA, 2009).
In addition to homology-based recombination processes, non-homologous (illegitimate)
recombination that does not require the presence of DNA similarity between the recombining DNA
molecules is theoretically possible. However, the transformation rates for illegitimate recombination
were considered to be 1010-fold lower than for homologous recombination (H€ulter and Wackernagel,
2008; EFSA, 2009) and have not never been detected for GM plants and bacteria, even in studies that
have directly exposed bacteria to high concentrations of GM plant DNA (EFSA, 2009).
The GMO Panel concludes that the aad-1 gene from maize DAS-40278-9 may, on a theoretical
basis, be transferred by homologous recombination to S. herbicidovorans and other bacteria with
sufﬁcient DNA sequence identity. However, since these bacteria are not considered to be members of
the gut microbiota, exposure to recombinant DNA of maize DAS-40278-9 is considered to be very low.
Owing to the occurrence of bacteria with natural variants of the aad-1 gene in the environment
including soil, a low level of gene replacement in S. herbicidovorans or related bacteria is not
considered a safety concern. Considering its intended use as food and feed and the above assessment,
50 Dossier: Part I – Section D6.
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the GMO Panel has therefore not identiﬁed a concern associated with a HGT from maize DAS-40278-9
to bacteria.
2) Plant-to-plant gene transfer
Considering the scope of application EFSA-GMO-NL-2010-89 and the biology of maize, the potential
of occasional feral GM maize plants originating from accidental spillage of imported grains to transfer
recombinant DNA to sexually cross-compatible plants is assessed. As pointed out above
(Section 3.4.1.1), occurrence of feral GM maize is expected to be limited.
The extent of cross-pollination to other maize varieties will mainly depend on the scale of accidental
release during transportation and processing and on successful establishment and subsequent
ﬂowering of the GM maize plant. For maize, vertical gene transfer is limited to other Zea species.
Populations of sexually compatible indigenous wild relatives of maize are not known in Europe
(Eastham and Sweet, 2002; OECD, 2003), therefore vertical gene transfer is not considered to be an
environmental issue in the EU.
The ﬂowering of occasional feral GM maize plants originating from accidental release during
transportation and processing is unlikely to lead to dispersal of signiﬁcant amounts of GM maize pollen
onto other maize plants. Field observations performed on maize volunteers after GM maize cultivation
in Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that
cross-pollinated neighbouring plants only at low levels (Palaudelmas et al., 2009). Thus, the likelihood
of cross-pollination between cultivated maize and the occasional feral maize plants resulting from grain
spillage is considered extremely low.
In conclusion, the GMO Panel is of the opinion that the likelihood of spread of genes from this GM
maize in Europe will not differ from that of conventional maize varieties, even in the case of treatment
with the intended herbicide.
Interactions of the GM plant and target organisms51
Considering the scope of application EFSA-GMO-NL-2010-89 and the absence of target pests,
potential interactions of the GM plant with target organisms are not considered a relevant issue by the
GMO Panel.
Interactions between the GM plant and non-target organisms52
Considering the scope of application EFSA-GMO-NL-2010-89 and the low level of exposure to the
environment, potential interactions of spilled grains or occasional feral maize DAS-40278-9 plants arising
from grain import spills with non-target organisms are not considered a relevant issue by the GMO Panel.
Interactions with the abiotic environment and biogeochemical cycles53
Considering the scope of application EFSA-GMO-NL-2010-89 and the low level of exposure to the
environment, potential interactions of spilled grains or occasional feral maize DAS-40278-9 plants
arising from grain import spills with the abiotic environment and biogeochemical cycles are not
considered a relevant issue by the GMO Panel.
3.4.1.2. Post-market environmental monitoring54
The objectives of a PMEM plan according to Annex VII of Directive 2001/18/EC are: (1) to conﬁrm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct; and (2) to identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment which were not anticipated in the ERA.
Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc content of the PMEM
plan provided by the applicant (EFSA, 2006b; EFSA GMO Panel, 2011b).
The PMEM plan proposed by the applicant for maize DAS-40278-9 includes: (1) the description of a
monitoring approach involving operators (federations involved in maize import and processing),
reporting to applicants, via a centralised system, any observed adverse effect(s) of GMOs on human
health and the environment; (2) a coordinating system newly established by EuropaBio for the
51 Dossier: Part I – Section D9.4.
52 Dossier: Part I – Section D9.5.
53 Dossier: Part I – Section D9.8 and D10.
54 Dossier: Part I – Section D11.
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collection of the information recorded by the various operators; and (3) the use of networks of existing
surveillance systems (Lecoq et al., 2007; Windels et al., 2008). The applicant proposes to submit a
PMEM report on an annual basis and a ﬁnal report at the end of the consent period.
The GMO Panel considers the scope of the PMEM plan provided by the applicant is consistent with
the scope of maize DAS-40278-9. As the ERA does not cover cultivation and did not identify potential
adverse environmental effects from maize DAS-40278-9, no case-speciﬁc monitoring is necessary. The
GMO Panel agrees with the reporting intervals proposed by the applicant in its PMEM plan.
3.4.2. Conclusion
No safety concerns with regard to the environment from the import and processing of maize
DAS-40278-9 were identiﬁed. There are no indications of an increased likelihood of establishment and
spread of occasional feral maize DAS-40278-9 plants in the case of accidental release into the
environment of viable GM maize grains, unless these plants are exposed to 2,4-D- or AOPP-containing
herbicides. The GMO Panel is of the opinion that this will not result in different environmental impacts
compared to conventional maize. The unlikely, but theoretically possible, horizontal transfer of the
recombinant gene from maize DAS-40278-9 to bacteria does not raise any environmental safety
concern. Considering the scope of the application, potential interactions of maize DAS-40278-9 with
the biotic and abiotic environment were not considered a relevant issue by the GMO Panel. The scope
of the PMEM plan provided by the applicant and the reporting intervals are in line with the intended
uses of maize DAS-40278-9 and the GMO Panel guidelines on the PMEM of GM plants (EFSA, 2006b;
EFSA GMO Panel, 2011b).
4. Conclusions
The EFSA GMO Panel was asked to carry out a scientiﬁc assessment of maize DAS-40278-9 for
import, processing, and food and feed uses in accordance with Regulation (EC) No 1829/2003.
The molecular characterisation data provided for maize DAS-40278-9 did not raise safety issues.
The GMO Panel concluded that none of the differences identiﬁed in the compositional, agronomic
and phenotypic characteristics of maize DAS-40278-9 required further assessment regarding food and
feed safety.
No concerns regarding the potential toxicity or allergenicity of the newly expressed AAD-1 protein
were identiﬁed, and no evidence that the genetic modiﬁcation might signiﬁcantly change the overall
allergenicity of maize DAS-40278-9 was found. The nutritional value of food and feed derived from
maize DAS-40278-9 is not expected to differ from that of food and feed derived from non-GM maize
varieties. The GMO Panel concludes that maize DAS-40278-9, assessed in this application, is as safe
and as nutritious as its non-GM comparator and the non-GM maize reference varieties tested.
Considering the scope of the maize DAS-40278-9 application, which excludes cultivation, there is no
requirement for a scientiﬁc assessment of possible environmental effects associated with the cultivation
of this GM maize. The GMO Panel concluded that there is a very low likelihood of environmental effects
resulting from the accidental release of viable seeds from maize DAS-40278-9 into the environment.
The unlikely, but theoretically possible, horizontal transfer of the recombinant gene from maize
DAS-40278-9 to bacteria does not raise any environmental safety concern. Considering the scope of the
application, potential interactions of maize DAS-40278-9 with the biotic and abiotic environment were
not considered a relevant issue by the GMO Panel. The scope of the PMEM plan provided by the
applicant and the reporting intervals are in line with the intended uses of maize DAS-40278-9 and the
GMO Panel guidelines on the PMEM of GM plants (EFSA, 2006b; EFSA GMO Panel, 2011b).
In conclusion, the GMO Panel considers that the information available for maize DAS-40278-9
addresses the scientiﬁc comments raised by the Member States and that maize DAS-40278-9, as
described in this application, is as safe as the non-GM comparator and other non-GM maize varieties
with respect to potential effects on human and animal health and the environment in the context of
the scope of this application.
Documentation provided to EFSA
1) Letter from the Competent Authority of the Netherlands received on 11 November 2010
concerning a request for placing on the market of herbicide-tolerant genetically modiﬁed
maize DAS-40278-9, application EFSA-GMO-NL-2010-89, submitted by DOW AgroSciences
LLC in accordance with Regulation (EC) No 1829/2003.
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2) Acknowledgement letter dated 7 December 2010 from EFSA to the Dutch Competent
Authority.
3) Letter from EFSA to applicant dated 20 December 2010 requesting additional information
under completeness check.
4) Letter from applicant to EFSA received on 20 January 2011 providing additional information
under completeness check.
5) Letter from EFSA to applicant dated 9 February 2011 requesting additional information
under completeness check.
6) Letter from applicant to EFSA received on 18 February 2011 providing additional
information under completeness check.
7) Letter from EFSA to applicant dated 11 March 2011 delivering the ‘Statement of Validity’ of
application for the authorisation herbicide-tolerant genetically modiﬁed maize DAS-40278-
9, application EFSA-GMO-NL-2010-89, submitted by DOW AgroSciences LLC in accordance
with Regulation (EC) No 1829/2003.
8) Letter from applicant to EFSA received on 5 April 2011 providing additional information
spontaneously.
9) Letter from EFSA to applicant dated 11 May 2011 requesting additional information and
stopping the clock on behalf of the DG JRC/EURL-GMFF.
10) Letter from EFSA to applicant dated 20 May 2011 requesting additional information and
maintaining the clock stopped.
11) Letter from applicant to EFSA received on 6 July 2011 providing a timeline for submission
of responses.
12) Letter from applicant to EFSA received on 7 December 2011 changing the previous
timeline for submission of responses.
13) Letter from applicant to EFSA received on 1 February 2012 providing additional
information.
14) Letter from EFSA to applicant dated 1 June 2012 re-starting the clock.
15) Letter from applicant to EFSA received on 2 July 2012 providing additional information
spontaneously.
16) Letter from applicant to EFSA received on 24 August 2012 providing additional information
spontaneously.
17) Letter from EFSA to applicant dated 7 September 2012 requesting additional information
and stopping the clock.
18) Letter from applicant to EFSA received on 19 November 2012 providing a timeline for
submission of responses.
19) Letter from applicant to EFSA received on 19 April 2013 changing the previous timeline for
submission of responses.
20) Letter from applicant to EFSA received on 25 November 2013 changing the previous
timeline for submission of responses.
21) Letter from applicant to EFSA received on 29 January 2014 providing additional
information.
22) Letter from EFSA to applicant dated 21 May 2014 requesting additional information and
maintaining the clock stopped.
23) Letter from EFSA to applicant dated 19 June 2014 requesting additional information and
maintaining the clock stopped.
24) Letter from EFSA to applicant dated 7 July 2014 annulling question No 6 sent in the EFSA
letter dated 21 May 2014 (Ref. EW/ZD/MR/lg(2014) 8784583).
25) Letter from EFSA to applicant dated 16 July 2014 requesting a timeline for submission of
responses.
26) Letter from applicant to EFSA received on 23 July 2014 providing additional information.
27) Letter from applicant to EFSA received on 29 July 2014 providing additional information.
28) Letter from applicant to EFSA received on 4 November 2014 providing additional
information spontaneously.
29) Letter from EFSA to applicant dated 18 November 2014 requesting additional information
and maintaining the clock stopped.
30) Letter from applicant to EFSA received on 16 December 2014 providing additional
information.
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31) Letter from EFSA to applicant dated 19 February 2015 requesting additional information
and maintaining the clock stopped.
32) Letter from EFSA to applicant dated 27 February 2015 requesting additional information
and maintaining the clock stopped.
33) Letter from applicant to EFSA received on 12 March 2015 providing additional information (I).
34) Letter from applicant to EFSA received on 12 March 2015 providing additional information (II).
35) Letter from EFSA to applicant dated 27 March 2015 requesting additional information and
maintaining the clock stopped.
36) Letter from applicant to EFSA received on 7 April 2015 providing additional information.
37) Letter from EFSA to applicant dated 14 April 2015 requesting additional information and
maintaining the clock stopped.
38) Letter from EFSA to applicant dated 24 April 2015 requesting additional information and
maintaining the clock stopped.
39) Letter from applicant to EFSA received on 27 April 2015 providing additional information.
40) Letter from applicant to EFSA received on 1 June 2015 providing additional information.
41) Letter from EFSA to applicant dated 17 July 2015 requesting additional information and
maintaining the clock stopped.
42) Letter from applicant to EFSA received on 24 August 2015 providing additional information.
43) Letter from EFSA to applicant dated 19 October 2015 requesting additional information and
maintaining the clock stopped.
44) Letter from EFSA to applicant dated 11 April 2016 requesting a timeline for responses
regarding the additional information requested on 19 October 2015 and on 11 April 2016.
45) Letter from applicant to EFSA received on 13 April 2016 providing a timeline for submission
of responses requested by EFSA on 11 April 2016.
46) Letter from EURL-GMFF dated 22 April 2016 requesting EFSA to stop the clock on behalf of
EURL-GMFF.
47) Email from EFSA to applicant dated 26 April 2016 maintaining the clock stopped due to
questions requested by EURL-GMFF.
48) Letter from applicant to EFSA received on 9 August 2016 providing additional information.
49) Letter from applicant to EFSA received on 9 August 2016 providing additional information
spontaneously.
50) Email from EFSA to applicant dated 11 August 2016 maintaining the clock stopped pending
additional information requested.
51) Letter from EURL to EFSA dated 7 September 2016 requesting EFSA to re-start the clock
on behalf of EURL-GMFF.
52) Letter from EFSA to applicant dated 8 September 2016 re-starting the clock.
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Abbreviations
2,4-D 2,4-dichlorophenoxyacetic acid herbicide
AAD-1 aryloxyalkanoate dioxygenase-1
ADF acid detergent ﬁbre
ALP alkaline phosphatase
ANOVA analysis of variance
AOPP aryloxyphenoxypropionate herbicide
BSA bovine serum albumin
bw body weight
DM dry matter
ELISA enzyme-linked immunosorbent assay
ERA environmental risk assessment
ESI-LS electrospray ionisation-liquid chromatography
EURL-GMFF European Union Reference Laboratory for GM Food & Feed
FAO Food and Agricultural Organisation of the United Nations
GLP Good Laboratory Practice
GM genetically modiﬁed
GMO genetically modiﬁed organism
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
Hb haemoglobin
HGT horizontal gene transfer
IgE immunoglobulin E
MALDI-TOF MS matrix-assisted laser desorption/ionisation time-of-ﬂight mass spectrometry
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MS mass spectrometry
NDF neutral detergent ﬁbre
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PCR polymerase chain reaction
PMEM post-market environmental monitoring
RBC red blood cells
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
UTR untranslated region
WBC white blood cells
WHO World Health Organisation
Zm Zea mays
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